Rewrite Biology

By RewriteBiology “What if everything we thought we knew about aging, menopause, and disease was wrong—and the key to preventing Alzheimer’s, diabetes, and heart disease was hiding in plain sight?” Why I Wrote This As a self-taught researcher, I've spent years studying the patterns of disease and blind spots in modern medicine. What I found was surprising: many chronic illnesses may stem from a misunderstood biological shift— menopause , in both men and women. This isn’t just about hormones. It’s about how a midlife shift marks the tipping point where pathogens overwhelm the immune system—leading to aging, neurological decline, and nearly all chronic diseases . From Crisis to Breakthrough Pharma is evolving, but current strategies still treat symptoms—not causes. What if Alzheimer’s , diabetes , and cancer all stem from the same failure in regeneration and immune control? What if it all starts around menopause? Menopause: The Overlooked Turning Point RewriteBiology r...

When smarter algorithms hit the wall of outdated biology In 2021, venture capitalists poured over $2 billion into AI-powered drug discovery startups. The hope was clear: artificial intelligence could compress a 10-year, multi-billion-dollar R&D cycle into a few years and a few million dollars. Companies like Recursion , Exscientia , and Insilico Medicine emerged as poster children for this new era, promising a revolution that would change the trajectory of pharmaceutical research forever. But fast forward to 2025, and the story looks much different. Stock prices are down. Investors are wary. M&A activity is heating up—not because of success, but because of pressure to survive. What happened? ⸻ 💡 AI Was a Tool, Not a Cure AI drug discovery promised efficiency: faster molecule generation, better hit prediction, and streamlined clinical trial design. In some areas—like protein structure prediction (e.g., AlphaFold)—it delivered. But the ...